A Phase 1, Randomized, Open-Label, 2-Period, 2-Sequence, 2-Way Crossover Study to Assess the Effect of Food on the Single Dose Pharmacokinetics of Acoramidis in Healthy Participants
Latest Information Update: 06 Nov 2023
At a glance
- Drugs Acoramidis (Primary)
- Indications Transthyretin-related hereditary amyloidosis
- Focus Pharmacokinetics
- Sponsors Alexion AstraZeneca Rare Disease
- 21 Sep 2021 Status changed from not yet recruiting to completed.
- 15 Jul 2021 New trial record